1700018G05Rik Inhibitors
Chemical inhibitors of the protein 1700018G05Rik can impede its function through various mechanisms related to cell cycle regulation. Alsterpaullone, a cyclin-dependent kinase (CDK) inhibitor, can inhibit the activity of CDK1, a kinase essential for cell cycle progression, which in turn can inhibit 1700018G05Rik by blocking necessary cell cycle events. Similar in their action, PD0332991 and Palbociclib can selectively inhibit CDK4/6, and by doing so, they can halt the cell cycle at the G1-S transition, a critical phase for 1700018G05Rik function. Roscovitine and Olomoucine offer a broader approach by targeting multiple CDKs, which can lead to the inhibition of phosphorylation and activation of proteins involved in cell cycle control, thus affecting 1700018G05Rik activity. Purvalanol A is another potent inhibitor, primarily affecting CDK1, CDK2, and CDK4, which can alter the cell cycle-regulated activities of 1700018G05Rik.
Other chemicals such as Indirubin-3'-monoxime can disrupt kinase activities by inhibiting CDKs and GSK-3beta, which are integral to cell signaling pathways and processes that 1700018G05Rik may rely on. Flavopiridol broadens this approach by inhibiting several CDKs involved in not only cell cycle regulation but also transcriptional control, which can prevent phosphorylation events essential for 1700018G05Rik function. Dinaciclib, a robust CDK inhibitor, can disrupt cell cycle progression and transcriptional regulation by inhibiting key CDKs like CDK1, CDK2, CDK5, and CDK9, affecting 1700018G05Rik's functional state. Seliciclib targets CDK2, CDK7, and CDK9, which can modify the cell cycle and transcription machinery crucial for 1700018G05Rik's activity. Lastly, AZD5438 and Ribociclib can impair cell cycle progression and transcriptional regulation by inhibiting CDK1, CDK2, and CDK9 for AZD5438, and selectively inhibiting CDK4/6 for Ribociclib, impacting the functional state of 1700018G05Rik. Each of these inhibitors can affect 1700018G05Rik by altering the cellular environment and the signaling pathways in which it operates.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases such as CDK1, which are integral to cell cycle progression. Inhibiting these kinases can lead to a downstream inhibition of 1700018G05Rik by preventing cell cycle events that are necessary for its function. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of CDK4/6, which could inhibit 1700018G05Rik by preventing cell cycle progression, thus affecting the protein's role in cell cycle-dependent functions. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine targets multiple CDKs, which could inhibit the phosphorylation and activation of proteins involved in cell cycle control, potentially leading to the functional inhibition of 1700018G05Rik. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a selective inhibitor of CDKs, specifically CDK1, CDK2, and CDK3. By inhibiting these kinases, the phosphorylation events necessary for cell cycle progression and for the optimal activity of 1700018G05Rik are hindered. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is a potent inhibitor of CDKs, especially CDK1, CDK2, and CDK4, affecting the cell cycle progression and thereby possibly inhibiting the function of 1700018G05Rik by altering its cell cycle-regulated activities. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
Indirubin-3'-monoxime inhibits CDKs and GSK-3beta, which could lead to an inhibition of 1700018G05Rik by disrupting the cell signaling pathways and processes that rely on the kinase activities. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits several CDKs implicated in cell cycle regulation and transcriptional control, which could inhibit the activity of 1700018G05Rik by preventing phosphorylation events that are necessary for its function. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib strongly inhibits CDKs, particularly CDK1, CDK2, CDK5, and CDK9, which can inhibit 1700018G05Rik through disrupting cell cycle progression and transcriptional regulation processes that may be crucial for its activity. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 inhibits CDK1, CDK2, and CDK9, which could inhibit 1700018G05Rik by impairing cell cycle progression and transcriptional regulation, thereby affecting the protein's functional state. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib selectively inhibits CDK4/6, which could inhibit 1700018G05Rik by halting cell cycle progression at the G1-S transition, affecting processes that are necessary for the protein's activity. | ||||||